摘要
目的探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)治疗应用于化疗后胰腺癌患者的临床效果,为胰腺癌的临床治疗提供可参考依据。方法选取郑州人民医院收治的诊断为胰腺癌的患者60例,采用随机数字法平均分为观察组和对照组两组,各30例。在常规治疗基础上,观察组患者采用化疗联合自身DC-CIK细胞进行治疗,对照组采用单纯化疗治疗。分别于治疗前、治疗后检测患者外周血中T细胞亚群及CD4+CD25+CDl27low调节性T细胞和IFN-γ及IL-4水平的变化,并随访3年,观察患者生存率。结果治疗后观察组患者CD3+、CD4+、CD3+CD56+百分率、CD4+/CD8+值上升,CD8+百分率、CD4+CD25+CDl27low下降,与治疗前相比差异有显著性(P<0.05);对照组患者CD3+、CD4+、CD8+、CD3+CD56+百分率、CD4+CD25+CDl27low均下降,与治疗前相比差异有显著性(P<0.05);治疗后观察组CD4+CD25+CDl27low下降较对照组更明显,两组间差异比较均有显著性(P<0.05)。治疗后观察组患者IFN-γ上升,IL-4水平下降,与治疗前相比均有显著性(P<0.05);而对照组患者IFN-γ及IL-4水平均下降,与治疗前相比均有显著性(P<0.05)。观察组患者1年生存率86.7%,3年生存率56.7%均高于对照组1年生存率63.3%,3年生存率30.0%,两组间差异比较均有显著性(P<0.05)。结论胰腺癌患者化疗后联合应用DC-CIK细胞治疗可以提高患者治疗的疗效,改善机体本身免疫平衡,增强机体T细胞免疫功能,提高患者的生存率,值得临床推广应用。
[Objectives] To study the effect of chemotherapy combined with DC-CIK cell in patients with pancre- atic cancer. [Methods] 60 patients with pancreatic caller were included in our hospital. All patients were divided into the observation group and the control group. Patients in the observation group were given chemotherapy com- bined with DC-CIK cell. Patients in the control group were only given chemotherapy. The levels of T cell subsets CD3＋,CIM＋,CD8＋, CD4＋CD25＋CD1271ow regulatory T cells were detected with flow cytometry and the IFN-1 and IIA were detected with ELISA in peripheral blood before and after the treatment. [Results] T cell subsets CD3＋, CD4＋ and CD3＋CD56＋, ratio of CD4＋/CD8＋ were increased after DC. CIK cell transfusion and the CD8＋ cell subsets and CD4＋CD25＋ CD1271ow regulatory T cells were significantly decreased （P 〈0.05）. The level of IFN-I was increased and the level of IL-4 decreased at the same time. In the control group, T cell subsets CD3＋, CD4＋, CD8＋ and CD4＋ CD25 ＋CD127 low regulatory T cells were decreased after treated with chemotherapy only （P 〈0.05）. The levels of IFN-γ/and [IA were decreased （P 〈0.01）. The 1 year survival rate and 3 year survival rate in observation group were 86.7%, 56.7%, respectively, which were higher than those in control group（63.3%, 30.0%）. The differences were sta- tistically significant （P 〈0.05）. [ Conclusions ] Chemotherapy combined with DC-CIK cell immunotherapy can im- prove the immune function of patients with pancreatic cancer and enhance the body anti-tumor effects, so it＇s one of means which were used to treat patients with pancreatic cancer.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第9期42-45,共4页
China Journal of Modern Medicine
关键词
树突状细胞
细胞因子诱导的杀伤细胞
化疗
胰腺癌
dendritic cells
cytokine induced killer cells
chemotherapy
pancreatic cancer
